Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data.

Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, Yang MH, Chen PM, Lin KP, Chiou TJ.

Support Care Cancer. 2006 May;14(5):484-7. Epub 2006 Feb 1.

PMID:
16450089
2.

Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.

Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chiou TJ, Liu JH, Yen CC, Chen PM.

Oncologist. 2007 Mar;12(3):312-9.

3.

Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.

Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E, Catalano G.

J Clin Oncol. 2002 Aug 15;20(16):3478-83.

PMID:
12177109
4.

[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].

Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C.

Dtsch Med Wochenschr. 2002 Jan 18;127(3):78-82. German.

PMID:
11797144
5.

Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies.

Ramanathan RK, Rothenberg ML, de Gramont A, Tournigand C, Goldberg RM, Gupta S, André T.

Ann Oncol. 2010 Apr;21(4):754-8. doi: 10.1093/annonc/mdp509. Epub 2009 Nov 3.

6.

Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.

Comella P, Massidda B, Palmeri S, Putzu C, De Rosa V, Izzo F, Fiore F, Casaretti R, Sandomenico C.

Anticancer Drugs. 2006 Sep;17(8):985-92.

PMID:
16940809
7.

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N.

J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30.

8.

Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.

Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Bower G, Shannon JA, Gibbs P, Steward WP.

J Clin Oncol. 2007 Mar 20;25(9):1099-106.

9.

Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.

Fuse N, Doi T, Ohtsu A, Takeuchi S, Kojima T, Taku K, Tahara M, Muto M, Asaka M, Yoshida S.

Jpn J Clin Oncol. 2007 Jun;37(6):434-9.

10.

[Analysis of a case of oxaliplatin - induced persistence sensory neuropathy].

Matsuo K, Higuchi M, Sasaki Y, Iwatsubo S, Wada Y, Hasegawa K, Shirakawa A, Mishima K, Iwasaki K, Fujiwara M, Nishino H.

Gan To Kagaku Ryoho. 2010 Mar;37(3):551-4. Japanese.

PMID:
20332703
11.
12.

Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N.

J Clin Oncol. 2007 Jun 1;25(16):2205-11. Epub 2007 Apr 30.

13.

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A.

J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18.

14.

Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.

Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L.

Anticancer Drugs. 2009 Jun;20(5):396-402. doi: 10.1097/CAD.0b013e32832a2dc1.

PMID:
19287306
15.
16.

Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer.

Choi J, Kong K, Mozaffar T, Holcombe RF.

Anticancer Drugs. 2006 Jan;17(1):103-5.

PMID:
16317297
17.

Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.

Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M, Francini G.

Cancer Chemother Pharmacol. 2008 Jan;61(1):105-11. Epub 2007 Apr 12.

PMID:
17429632
18.

Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.

Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, Wilding GE, Fakih MG.

Oncology. 2009;76(5):363-8. doi: 10.1159/000210025. Epub 2009 Mar 25.

PMID:
19321964
19.

Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.

Chay WY, Tan SH, Lo YL, Ong SY, Ng HC, Gao F, Koo WH, Choo SP.

Asia Pac J Clin Oncol. 2010 Dec;6(4):270-7. doi: 10.1111/j.1743-7563.2010.01344.x.

PMID:
21114776
20.

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC.

Brain. 2009 Oct;132(Pt 10):2712-23. doi: 10.1093/brain/awp219. Epub 2009 Sep 10.

Items per page

Supplemental Content

Write to the Help Desk